Basal Cell Carcinoma
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Subtype terms (1)
More specific conditions that are subtypes of Basal Cell Carcinoma in the MeSH hierarchy.
- Basal Cell Nevus Syndrome
17 drugs (13 approved, 4 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (3)
Phase 3 trials (6)
Phase 2 trials (53)
- diclofenac
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- aluminum
- human fibrin
- Gusacitinib
- bo-112
- irinotecan
- cmp-001
- prednisone
- doxorubicin
- escharex
- ingenol mebutate
- nivolumab
- saridegib
- pembrolizumab
- l19il2
- leucovorin
- T4-bacteriophage endonuclease V
- ltx-315
- oshadi d
- pd-l1 peptide vaccine
- methylene blue
- resiquimod
- ipilimumab
- hyaluronic acid
- retinostat
- sirolimus
- 3,4-Methylenedioxymethamphetamine
- stp705
- bevacizumab
- +23 more
Phase 1 trials (26)
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (54)
- Peplin
- Regeneron
- Roche
- Merck
- Sanofi
- Stamford Pharmaceuticals
- Inhibitor Therapeutics
- Oncovir, Inc.
- Oshadi Drug Administration
- Philogen S.p.A.
- Sirnaomics
- Spirig Pharma Ltd.
- SRH Wald-Klinikum Gera GmbH
- Berg, LLC
- National Cancer Institute (NCI)
- Shahid Beheshti University of Medical Sciences
- University of Arizona
- Johns Hopkins University
- Loma Linda University
- McGill University
- Melanoma Institute Australia
- Oregon Health and Science University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- University of Manchester
- University of Tampere
- University of Toronto
- St. Louis University
- University of California, San Francisco
- +24 more
Organization Involved with Phase 1 Indications (30)
- Incyte
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Exelixis
- Biosceptre
- Senhwa Biosciences, Inc.
- Translational Drug Development
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cornell University
- Harvard University
- Temple University
- University of Kansas
- University of Rochester
- University of Virginia
- University of Zurich
- University of Chicago
- University of Colorado, Denver
- Vanderbilt University
- Xencor
- TKL Research
- State University of New York, Buffalo
- Washington University in St. Louis
- ICON
- The Cleveland Clinic
- InClinica, Inc.
- SkinJect, Inc.
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Genzada Pharmaceuticals
- Center for Biomedical Research, Inc.
Organization Involved with Other Experimental Indications (15)
- Galderma
- Infinity Pharmaceuticals, Inc.
- Federal University of Health Science of Porto Alegre
- University of Washington
- Norwegian University of Science and Technology
- Osaka University
- University of Bergen
- Mayo Clinic
- Western Infirmary
- Hudlegekontoret Lillehammer
- V Foundation
- University of Stavanger
- Yeshiva University
- Ghent University
- Oslo Metropolitan University